Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Is ABO Blood Group a CV Risk Factor in FH Patients?

J Clin Lipidol; ePub 2017 Dec 13; Paquette, et al

A non-O blood group is associated with an independent 2-fold increased risk of cardiovascular disease (CVD) in patients with familial hypercholesterolemia (FH), a recent study found. The study examined the effect of the ABO blood group on CVD risk in 668 adult participants with a heterozygous FH-causing mutation in the low-density lipoprotein receptor (LDLR) gene. ABO blood group was determined using 2 functional single-nucleotide polymorphisms in the ABO gene. Researchers found:

  • Total cholesterol was significantly higher in non-O subjects compared to carriers of the O group.
  • A greater proportion of participants carrying the non-O groups was observed in patients with CVD vs those without CVD (73.4% vs 63.3%).
  • The non-O group was significantly associated with an increased prevalence of CVD (odds ratio, 2.14).
  • Patients in the non-O blood group experienced more CVD events vs those in the O group (0.88 per individual vs 0.60).

Citation:

Paquette M, Dufour R, Baass A. ABO blood group is a cardiovascular risk factor in patients with familial hypercholesterolemia. [Published online ahead of print December 13, 2017]. J Clin Lipidol. doi:10.1016/j.jacl.2017.12.001.

This Week's Must Reads

Lipid Testing After Acute Myocardial Infarction, J Am Heart Assoc; ePub 2018 Jan 25; Wang, et al

Clinical Pharmadynamics of Evolocumab, Clin Pharmacokinet; ePub 2018 Jan 20; Kasichayanula, et al

Lipoproteins & CV Outcomes in Dialysis Patients, J Clin Lipidol; ePub 2017 Dec 26; Kaysen, et al

Is Dual Lipid-Lowering Therapy Better?, Atherosclerosis; 2018 Feb; Gragnano, et al

sLOX-1 in Ischemic Stroke & Transient Ischemic Attack, J Am Heart Assoc; ePub 2018 Jan 12; Skarpengland, et al

Must Reads in Hypercholesterolemia

Lipid Testing After Acute Myocardial Infarction, J Am Heart Assoc; ePub 2018 Jan 25; Wang, et al

Clinical Pharmadynamics of Evolocumab, Clin Pharmacokinet; ePub 2018 Jan 20; Kasichayanula, et al

Lipoproteins & CV Outcomes in Dialysis Patients, J Clin Lipidol; ePub 2017 Dec 26; Kaysen, et al

Is Dual Lipid-Lowering Therapy Better?, Atherosclerosis; 2018 Feb; Gragnano, et al

sLOX-1 in Ischemic Stroke & Transient Ischemic Attack, J Am Heart Assoc; ePub 2018 Jan 12; Skarpengland, et al